anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Systems and techniques are disclosed for trust based access to records via encrypted protocol communications with an authentication system. One of the methods includes maintaining, in one or more databases, health records associated with patients. Each health record including portions of medical information and each portion being separately trustable to one or more outside entities. The trust indicating that an outside entity can access a portion. A request from a user device of a patient is received, the request indicating access to a health record associated with the patient. Requests for information are presented on the user device, the requests indicating features of patients that are usable to identify a specific patient. The patient uniquely corresponding to a particular health record is determined, and user account information for the patient is generated, with the user account information used to identify portions of medical information associated with the particular health record.
Currently, the only FDA-approved therapy for patients with AIDS or ARC is zidovudine (AZT), a drug with significant value but limited use because of toxic effects on the bone marrow. d4T has not been tested in humans, but it has inhibited the reproduction of HIV (the virus that causes AIDS) in laboratory experiments. In some studies with laboratory animals, d4T was less toxic against blood cells than AZT.

A maximum tolerated dose (MTD) has been found in Phase I trials to date. An MED will be determined. The daily dose of d4T is divided into 2 portions and administered approximately 12 hours apart for 10 weeks. 5 patients receive the initial dose level and successive groups of 5 patients enter the study at a lower dose level once 3 patients in the preceding group have successfully completed at least 3 weeks of dosing and shown a positive effect on CD4 cell count and p24 antigen levels. The initial group of patients continue dosing at their dose level for an additional 94 weeks as long as they are doing well as measured by p24 antigen levels and CD4 cell counts. The dose de-escalation scheme continues until a lack of efficacy is seen in 2 of 5 patients in any group. Patients are assigned to de-escalating dose level treatment groups in the order in which they are enrolled. Blood and urine samples are taken regularly to check for toxic effects and therapeutic effectiveness. In each dosing group, 3 of 5 patients will be p24 antigen positive greater than or equal to 70 pg/ml, and 2 of 5 patients will have CDC-defined AIDS.
Titratable candesartan with commencing dose 4mg tablets twice daily (daily dose 8 mg) + matched placebo repagermanium one capsule twice daily. Treatment will continue for 28 days.
In addition to the applications to the first group, mobilization, strengthening, posture and segmental breathing exercises will be given . All of these exercises will be combined with segmental breathing exercises depending on the location of the PC. Exercise therapy will be administered by a physiotherapist with 20 years of experience once a week and will be designed as a home program on the remaining days and will be asked to do 45 minutes twice a day (at least 4 times a week). The patient's relatives will be asked to keep a book to monitor the exercise. Patients who do not perform 5 consecutive exercise sessions will be excluded from the study. All treatments will be given for 12 weeks.
FIELD: organic chemistry. SUBSTANCE: product: derivatives of indole of the general formula (I) $$$ and their tautomeric general formula (Ia) $$$ and (Ib) $$$ where $$$ and $$$ were indicated in invention, mixtures of their isomers or the separate isomers and pharmaceutically acceptable salts. Other object of invention is pharmaceutical composition exhibiting antitumor activity, activity inhibiting protein tyrosine kinase activity and containing at least one pharmaceutically acceptable carrier and at least one active substance. Active substance is indole derivative of above indicated formula (I) $$$, (Ia) $$$ or (Ib) $$$, mixture of its isomers or the separate isomer, or its pharmaceutically acceptable salt taken at effective amount. Another object of invention is method of inhibition of protein tyrosine kinase-dependent disease or struggle against aberrant cell growth in mammalian or human that involves administration of an active substance. Active substance is at least one compound of above indicated general formula (I) $$$, (Ia) $$$ or (Ib) $$$, mixture of its isomers or the separate isomer, or its pharmaceutically acceptable salt at effective dose. EFFECT: improved method of synthesis, enhanced effectiveness of treatment.
OBJECTIVE: Social housing programs are integral to making housing more affordable to Canadian seniors living in poverty. Although the programs are similar across Canada, there may be inter-provincial differences among the health of residents that could guide the development of interventions. This study explores the health of low-income seniors living in social housing in Quebec and compares it with previously reported data from Ontario.
RESULTS: 80 responses were obtained in Quebec to compare with the previously reported Ontario data (n = 599) for a total of 679 responses. More Ontario residents had access to a family doctor (p < 0.001). Quebec residents experienced less problems with self-care (p = 0.017) and less mobility issues (p = 0.052). The visual analog scale for overall health state was similar in both provinces (mean = 67.36 in Ontario and 69.23 in Quebec). Residents in Quebec smoked more cigarettes per day (p = 0.009). More residents in Ontario participated in moderate physical activity (p = 0.09), however, they also spent more time per day on the computer (p = 0.006).
Prepackaged capsules taken 3 times per day. During the first month, the total dose will be 15 g/d. For months 2-4, the total dose will be 30 g/d.
The present invention discloses a method for preparing the raw liquor of an armilariella tabescens healthy product for strengthening the human body and protecting the liver, and for improving an preparation of armilariella tabescens. The technology adopts a method for the submerged fermentation of microbe liquor and for preparing traditional Chinese medicine. The method can increase the yield of the armilariella tabescens and improve the preparation of the armilariella tabescens. Referred technological processes comprise strain slant culturing, liquid seed culturing, and enlargement and fermentation besides traditional technological processes. The method for preparing comprises the following steps: slant culturing is carried out to the strains; slant seeds are coupled in a liquid seed medium; liquid seeds are coupled in a fermentation medium to be fermented; the strains are decolored and concentrated to form granules, tablets and capsules by collecting fermentation liquor and extracting the active ingredients of bacterial balls. The method effectively increases the yield of armilariella tabescens and improves the preparation of the armilariella tabescens.
This is a prospective randomized control study which will be conducted at six large ambulatory pediatrics clinics from the Jerusalem district. All of the children diagnosed with IDA would be eligible to join the study after informed consent will be obtained. Ethics committee approval is obtained. Analysis of stool samples will be carried out by the HP Stool antigen EIA (HpSA, Premier Platinum HpSA, Meridian Diagnostics inc, Cincinnati, OH, USA). All children enrolled will be treated with standard Fe therapy. Children with positive HpSA will be randomized, controlled for age and clinic, to receive or not receive antibiotics treatment. Assessment of response to iron therapy will be done at eight weeks later. The prevalence of HP infection in children with diagnosed with IDA would be reported. Statistical analysis will compare the baseline data between HP-positive and -negative children and the response to Fe between the three study groups.
Participants with human epidermal growth factor receptor 2 (HER2)-positive MBC will receive docetaxel (Doc) 75 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Day 1 and T-DM1 2.4 milligrams per kilogram (mg/kg) IV infusion on Day 2 of Cycle 1 followed by T-DM1 75 mg/m\^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 75 mg/m\^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
This is a control group. The candidates will be administered a single dose of 11.25mg GNRH analoge (Lucrin) only.
Effectiveness of SIMPONI in pediatric patients less than 18 years of age has not been established.

The safety and efficacy of SIMPONI were evaluated in a multicenter, placebo-controlled, double-blind, randomized-withdrawal, parallel group study in 173 children (2 to 17 years of age) with active polyarticular juvenile idiopathic arthritis (pJIA) despite treatment with MTX for at least 3 months. Subjects were maintained on their stable dose of MTX at the same dose (mg/week) at study entry. Concurrent use of stable doses of oral corticosteroids (≤10 mg/day or 0.2 mg/kg/day prednisone or equivalent, whichever was less) and/or NSAIDs was permitted. In the 16 week open-label phase, all patients received MTX and SIMPONI 30 mg/m 2(maximum 50 mg) subcutaneously every 4 weeks. Patients who achieved an ACR Ped 30 response at Week 16 entered the randomized-withdrawal phase of the study and received MTX and either SIMPONI 30 mg/m 2(maximum 50 mg) or placebo every 4 weeks through Week 48. 

The primary endpoint of the study was the proportion of patients who did not experience a flare between Week 16 and Week 48, among all subjects who entered the randomized withdrawal phase. The efficacy of SIMPONI in the treatment of pJIA was not demonstrated in this study because there was no statistical evidence of differences in flare rate between SIMPONI-treated patients and placebo patients between Weeks 16 and 48.

In this study, the frequency and type of the adverse reactions seen in children were generally similar to those observed in adults.
<P>PROBLEM TO BE SOLVED: To provide a core that has undergone a certain enrobing treatment such as an enrobed tablet core.  <P>SOLUTION: An enrobed a core, such as a tablet core, that has a coating made of one or more patterned films each having portions that are visually distinct (e.g., differently colored) from one another and having a transition line segment between these visually distinct portions. At least a portion of an outer surface of the core is covered with the film or films, such that the transition line segments form a substantially continuous transition line. Where the patterned films are bi-colored, the resulting enrobed core can be bi-colored, or the resulting enrobed core can have a coating with at least four visually distinct portions alternately arranged thereon, thereby forming a checkered pattern on the coating. In either case, the film seam of the coating is different from the transition line of the coating.  <P>COPYRIGHT: (C)2004,JPO
Growth differentiation factor 15 (GDF15), a member of the transforming growth factor-beta superfamily, is expressed in several human organs. In particular, it is highly expressed in the placenta, prostate, and liver. The expression of GDF15 increases under cellular stress and pathological conditions. Although numerous transcription factors directly up-regulate the expression of GDF15, the receptors and downstream mediators of GDF15 signal transduction in most tissues have not yet been determined. Glial cell-derived neurotrophic factor family receptor α-like protein was recently identified as a specific receptor that plays a mediating role in anorexia. However, the specific receptors of GDF15 in other tissues and organs remain unclear. As a marker of cell stress, GDF15 appears to exert different effects under different pathological conditions. Cell senescence may be an important pathogenetic process and could be used to assess the progression of various lung diseases, including COVID-19. As a key member of the senescence-associated secretory phenotype protein repertoire, GDF15 seems to be associated with mitochondrial dysfunction, although the specific molecular mechanism linking GDF15 expression with ageing remains to be elucidated. Here, we focus on research progress linking GDF15 expression with the pathogenesis of various chronic lung diseases, including neonatal bronchopulmonary dysplasia, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, and pulmonary hypertension, suggesting that GDF15 may be a key biomarker for diagnosis and prognosis. Thus, in this review, we aimed to provide new insights into the molecular biological mechanism and emerging clinical data associated with GDF15 in lung-related diseases, while highlighting promising research and clinical prospects.
Subchondral insufficiency fracture (SIF) represents a potentially severe condition that can advance to osteoarthritis, with collapse of the articular surface. SIF manifests as a fracture in bone weakened by non-tumorous disease, precipitated by repetitive physiological stress, without a clear history of major trauma. It is observed along the central weight-bearing region of the femoral condyle, with a higher incidence in the medial femoral condyle, but also in other large weight-bearing synovial joints, such as the femoral head, tibial plateau, or talus.A review of the literature from the past six years was performed by searching PubMed and ScienceDirect databases, using the keywords "subchondral insufficiency fracture" and "spontaneous osteonecrosis of the knee". The inclusion criteria were scientific papers presented in the English language that reported on the magnetic resonance imaging (MRI) aspects of SIF of the lower limb.Detecting SIF at the level of the hip, knee, and ankle may present challenges both clinically and radiologically. The MRI appearance is dominated by a bone marrow edema-like signal and subchondral bone changes that can sometimes be subtle. Subchondral abnormalities are more specific than the pattern of bone marrow edema-like signal and are best shown on T2-weighted and proton-density-weighted MR images. MRI plays an important role in accurately depicting even subtle subchondral fractures at the onset of the disease and proves valuable in follow-up, prognosis, and the differentiation of SIF from other conditions. · Subchondral insufficiency fractures may affect the hip, knee, and ankle.. · Subchondral insufficiency fractures may heal spontaneously or progress to collapse.. · MRI is important for the detection, follow-up, and prognosis of subchondral insufficiency fractures.. · Differential diagnosis may include transient osteoporosis and osteonecrosis of systemic origin.. · Buturoiu MM, Ghiea S, Weber M. Subchondral insufficiency fractures: overview of MRI findings from hip to ankle joint. Fortschr Röntgenstr 2024; 196: 1143 - 1154.
The invention discloses a Chinese herbal medicine composite for alleviation of lower respiratory tract disease. The herbal medicine composite comprises 5 to 9 portions of honeysuckle, 2 to 9 portions of schisandra seeds, 5 to 8 parts of Platycodon grandiflorum, 4 to 11 parts of bovista, 6 to 12 parts of flos daturae, 3 to 8 portions of senecio, 6 to 13 parts of Thory Elaeagnus Leaves, 5 to 13 parts of tussilago, 3 to 12 parts of aster, 2 to 7 parts of Rorippa indica. Through long time investigation and research of the symptoms and causes of respiratory diseases and the subsequent uses of Chinese herbal medicine formula the invention solves the lower respiratory tract diseases from the bottom. In comparison with the western medicine the Chinese herbal formula not only can relieve the coughing, sore throat, swallow pain and other symptoms, but also can root up the disease and prevent the symptoms from recurring; compared with the current Chinese herbal formula the formula in the invention has clear constitution. The healing effects of the preparation are more apparent. The medicine of the invention is suitable for the treatment of lower respiratory tract diseases triggered by various kinds of causes.
The present invention relates to a Jisuishenjing Zaisheng Dan-a Chinese medicine for curing spinal cord injury. Said invention uses the function of promoting blood circulation by removing blood stasis as the principle of medicine selection. It uses the Chinese medicines of saffron, pseudo-ginseng, prepared pangolin scales, ephedra and nux-vomica seed, etc. to form the invented prescription. Said invention can be used for treating traumatic paraplegia, and can notably promote the restoration and regeneration of spinal nerve function. Its total therapeutic effective rate can be up to 89.9%, obvious effective rate is 75%, and the rate of basically taking care of oneself in daily life is up to 57%.
NEW MATERIAL:The monoclonal antibody reacting specifically with human gastric cancer cells, and produced by the hybridoma obtained by the fusion of myeloma cell and immunized cell of mammal immunized with human gastric cancer cell. USE:Diagnotic for human gastric cancer. PROCESS:Cultured human carcinoma cells MKN74 are suspended in physiological saline water, and the suspension is infused into the peritoneal cavity of a Balb/c mouse three times with intervals of 2 weeks. 3 days after the final immunization, the spleen is extracted, and the spleen cells are washed, mixed with mouse myeloma cell strain NS/1, and subjected to cell fusion in the presence of polyethylene glycol. The obtained cell is inoculated in a medium containing hypoxanthine, aminopterin and thymidine (HAT medium) and cultured in a CO2 incubator to obtain hybridoma. The hybridoma is cloned by critical dilution method to obtain a monoclonal antibody-producing hybridoma, by which the antibody for human gastric cancer is produced.
The invention discloses an application of istradefylline in preparation of a drug for reversing drug resistance of tumor cells, and relates to the technical field of drug resistance treatment of tumor cells. The invention relates to a method for preparing medicine for reversing tumor paclitaxel drug resistance by combining istradefylline and paclitaxel. Researches find that the expression level of MDR1 gene and protein can be obviously reduced by the aid of the istradefylline, and the sensitivity of drug-resistant cells to chemotherapeutic drugs can be obviously improved by the combined use of the istradefylline and the chemotherapeutic drug taxol, so that the drug resistance of tumors is reversed, and the curative effect is greatly improved. Animal experiments also prove that the istradefylline can effectively inhibit the growth rate of subcutaneous tumors of drug-resistant animal models and reverse the drug resistance of paclitaxel. These results indicate that the combination of istradefylline and paclitaxel can effectively enhance the therapeutic effect of paclitaxel on resistant tumors. Clinical application shows that many malignant tumor cells have drug resistance to paclitaxel, so that the istradefylline has good development value and application prospect.
Coffee is the most popular beverage in the world and, aside from tea and water, the most often consumed caffeine-containing beverage. Because of its high caffeine concentration, it is typically classified as a stimulant. There are other bioactive ingredients in coffee besides caffeine. The coffee beverage is a blend of several bioactive substances, including diterpenes (cafestol and kahweol), alkaloids (caffeine and trigonelline), and polyphenols (particularly chlorogenic acids in green beans and caffeic acid in roasted coffee beans). Caffeine has also been linked to additional beneficial benefits such as antioxidant and anti-inflammatory properties, which change cellular redox and inflammatory status in a dose-dependent manner. Pyrocatechol, a constituent of roasted coffee that is created when chlorogenic acid is thermally broken down, has anti-inflammatory properties as well. It is postulated that coffee consumption reduces neuroinflammation, which is intimately linked to the onset of neurodegenerative disorders like Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD). This review provides an overview of the most recent studies regarding coffee's possible benefits in preventing brain inflammation and neurodegenerative disorders.
BACKGROUND: Compound Danshen dripping pills (CDDP), a traditional Chinese medicine, has had an extensive application in the treatment of angina pectoris (AP) in China. However, research on the bioactive ingredients and underlying mechanisms of CDDP in AP remains unclear.
OBJECTIVE: In the present study, we explored the major chemical components and potential molecular mechanisms linked to the anti-angina effects of CDDP through the application of network pharmacology and molecular docking.
METHODS: The potential targets of active ingredients in CDDP were sourced from the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) and the Swiss Target Prediction Database (STPD). Additionally, targets related to angina pectoris (AP) were retrieved from various databases, including Gene Cards, DisGeNET, Dis Genet, the Drug Bank database (DBD), and the Therapeutic Target Database (TDD). Protein- protein interaction networks were also established, and core targets were identified based on their topological significance. GO enrichment analysis and KEGG pathway analysis were conducted using the R software. Interactions between active ingredients and potential targets selected through the above process were investigated through molecular docking.
RESULTS: Seventy-six active ingredients were selected with the following criteria: OB ≥ 30%, DL ≥ 0.18. 383 targets of CDDP and 1488 targets on AP were gathered, respectively. Afterwards, 194 common targets of CDDP and anti-AP targets were defined, of which 12 were core targets. GO enrichment analysis indicated that CDDP acted on AP by response to lipopolysaccharide, regulating the reactive oxygen species and metal ion metabolism, and epithelial cell proliferation. In addition, KEGG enrichment analysis indicated that the signaling pathways were notably enriched in lipid and atherosclerosis, fluid shear stress and atherosclerosis, IL-17 signaling pathway, EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, and TNF signaling pathway. Moreover, the molecular docking manifested excellent binding capacity between the active ingredients and targets on AP.
CONCLUSION: This study comprehensively illustrated the bioactive, potential targets, and molecular mechanisms of CDDP against AP, offering fresh perspectives into the molecular mechanisms of CDDP in preventing and treating AP.
Behçet's syndrome (BS) is a rare multisystem vasculitis involving blood vessels of any size. BS aetiology is still unclear to date, and the heterogeneity of clinical expression among ethnics and genders make early diagnosis challenging. However, so far, considerable efforts have been made toward the understanding of BS, leading researchers to agree that the coexistence of some environmental triggers and a genetical susceptibility both underlie BS aetiopathogenesis. In particular, viral agents, oral microbial flora, and mucosal microbiota have been widely explored in this regard, but still no specific microorganism has been definitely linked to the disease aetiology. Likewise, the concept that some environmental factors may play a role in BS clinical presentation has emerged based on the growing evidence that disease severity is usually higher in male patients, and that diet and fatigue may be involved in disease recurrence, especially in mucocutaneous manifestations. Moreover, smoke cessation is acknowledged as a risk factor for oral ulcerations, although the underlying mechanism is still not clear. All those environmental factors play their effects through epigenetic mechanisms. The aim of this review is to discuss the evidence on the role of environmental factors in BS aetiopathogenesis and clinical course.